Teva Pharma (NYSE: TEVA) reported Q1 EPS of $0.52, $0.04 better than the analyst estimate of $0.48. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.98 billion.

GUIDANCE:

Teva Pharma sees FY2025 EPS of $2.45-$2.65, versus the consensus of $2.56. Teva Pharma sees FY2025 revenue of $16.8-17.2 billion, versus the consensus of $17.243 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.